
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics Inc. has demonstrated significant advancements in its clinical pipeline, with DYNE-251 showing a ~7% increase in dystrophin expression and favorable safety outcomes during Phase I trials. Additionally, DYNE-101 has delivered meaningful improvements in disease biomarkers and functional outcomes, indicating a positive trajectory for the therapeutic's efficacy and potential accelerated approval in 2026. The company's ability to enrich patient groups and achieve stable dystrophin levels further reinforces the promising clinical profile of its therapies, suggesting a strong potential for success in future clinical advancements.
Bears say
Dyne Therapeutics faces significant financial challenges, primarily due to concerns regarding the efficacy and safety profiles of its therapeutic candidates, particularly DYNE-101 and DYNE-251, with recent data indicating a stark decline in efficacy over time. Additionally, potential payer headwinds related to reimbursements for DYNE-251 following prior treatments further complicate the outlook, posing risks to revenue generation. Moreover, any emerging safety concerns during clinical trials could severely hinder commercial uptake and negatively impact the company's stock performance.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares